BRAF and non-small cell lung carcinoma: Given the results obtained in patients with advanced melanoma [7,8], BRAF inhibitors, such as dabrafenib and vemurafenib, were also evaluated in patients with advanced NSCLC and BRAF mutations, showing promising outcomes [9,10,11].